UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies

University of Arkansas

Overview

The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Conditions

Multiple Myeloma

Interventions

TransfusionPROCEDURE

Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with advanced hematological malignancies who have failed at least two lines of therapy. * Karnofsky performance score \> 60, unless due to disease and then \> 50. * Age \> 18 years. * An expected survival of \> 3 months. * Subjects must have signed an IRB-approved consent and been informed about the investigational nature of the study. * Cord blood must have negative serology for HIV. * Release of cord blood. * The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient body weight. Exclusion Criteria: * Liver function: total bilirubin \> 2x ULN or AST/ALT \> 3x ULN. * Creatinine \> 3.0 mg/dL.

Locations (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Outcomes

Primary Outcomes

The researchers on this study want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.

Time frame: 12 months

Secondary Outcomes

The researchers also want to find out what types of side effects, if any, subjects will experience with this treatment.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.